Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity

医学 射血分数 心力衰竭 心脏病学 内科学 肥胖 2型糖尿病 糖尿病 分数(化学) 内分泌学 有机化学 化学
作者
Milton Packer,Michael R. Zile,Christopher M. Kramer,Joseph M DiMaria,Seth J. Baum,Sheldon E. Litwin,Masahiro Murakami,Chunmei Zhou,Yang Ou,Lisette Koeneman,Barry A. Borlaug
出处
期刊:Journal of the American College of Cardiology [Elsevier BV]
卷期号:86 (10): 696-707 被引量:35
标识
DOI:10.1016/j.jacc.2025.06.058
摘要

BackgroundIncretin-based therapies are used to treat type 2 diabetes and obesity, but the presence of diabetes diminishes the magnitude of weight loss produced by these drugs in people with obesity. It is not known whether this attenuated weight change is relevant to the clinical benefits of these drugs in heart failure. ObjectivesThe goal of this study was to assess the influence of diabetes on the efficacy and safety of tirzepatide in the SUMMIT trial. MethodsIn a double-blind trial, 731 patients with heart failure and a preserved ejection fraction (HFpEF) with a body mass index ≥30 kg/m2 were randomly assigned in a 1:1 ratio to receive tirzepatide (up to 15 mg subcutaneously weekly) or placebo for a median of 104 weeks. History of diabetes was a stratification variable for randomization. The 2 primary outcomes were: 1) time to first cardiovascular death or worsening heart failure event; and 2) change in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score at 52 weeks. Paired cardiac magnetic resonance imaging was used to assess changes in left ventricular mass and paracardiac fat at 52 weeks. ResultsOverall, cardiovascular death or worsening heart failure events occurred less frequently in the tirzepatide group (HR: 0.62; 95% CI: 0.41-0.95; P = 0.026), primarily related to fewer worsening heart failure events. The effect in patients with or without diabetes was similar: HR of 0.64 (95% CI: 0.35-1.15) in patients with diabetes and 0.61 (95% CI: 0.33-1.10) in patients without diabetes (Pinteraction = 0.95). The magnitude of the improvement in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score, 6-minute walk distance, quality-of-life scores, and NYHA functional class with tirzepatide was statistically significant and did not differ in patients with and without type 2 diabetes. At 52 weeks, weight loss was less pronounced in patients with type 2 diabetes; patients with diabetes lost 10.4% (95% CI: 8.7%-12.2%) of body weight, compared with 12.9% (95% CI: 11.2%-14.6%) in patients without diabetes (Pinteraction = 0.04). However, patients with or without diabetes showed similar decreases in visceral adiposity (as reflected by the decline in paracardiac fat) and in left ventricular mass. ConclusionsDespite less pronounced weight loss, patients with HFpEF, obesity, and type 2 diabetes responded favorably to tirzepatide. This favorable response was reflected by a reduced risk of adverse heart failure outcomes and improved health status, quality of life, and functional capacity, as well as a decrease in left ventricular mass and paracardiac fat, to a degree that was similar to that in patients without diabetes. These observations raise the possibility that the heart failure benefits of incretin-based drugs may not be faithfully estimated by measuring the magnitude of the change in body weight. (SUMMIT [A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity]; NCT04847557)
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
sa0022完成签到,获得积分10
2秒前
hj完成签到,获得积分10
2秒前
敏感的飞松完成签到 ,获得积分10
2秒前
蘑菇完成签到,获得积分10
5秒前
xia23完成签到,获得积分10
5秒前
Thunnus001完成签到 ,获得积分10
6秒前
xuan2022完成签到,获得积分10
7秒前
inoo完成签到 ,获得积分10
7秒前
这就是你的回答吗完成签到 ,获得积分10
8秒前
10秒前
WSY完成签到 ,获得积分10
10秒前
Orange的应助被nav采纳,获得10
10秒前
WXyue完成签到 ,获得积分10
10秒前
科研王子完成签到 ,获得积分10
10秒前
11秒前
桃子完成签到 ,获得积分10
11秒前
12秒前
JUAN完成签到,获得积分10
13秒前
lihui完成签到,获得积分10
13秒前
滿分選手完成签到 ,获得积分10
14秒前
Xu发布了新的文献求助10
17秒前
18秒前
常青树完成签到,获得积分10
24秒前
chaoschen完成签到,获得积分10
27秒前
Hello的应助被称心访卉采纳,获得10
28秒前
MADAO完成签到 ,获得积分10
29秒前
ebao完成签到 ,获得积分10
29秒前
Chief完成签到,获得积分0
31秒前
积极的白羊完成签到 ,获得积分10
31秒前
Badge完成签到 ,获得积分10
32秒前
lizi完成签到 ,获得积分10
33秒前
朱佳宁完成签到 ,获得积分10
33秒前
lamer完成签到,获得积分10
34秒前
34秒前
weng完成签到,获得积分10
35秒前
36秒前
哈哈哈哈哈完成签到,获得积分10
38秒前
细腻问柳完成签到,获得积分10
38秒前
李昕蓥完成签到 ,获得积分10
40秒前
16601107082发布了新的文献求助10
40秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166556
求助须知:如何正确求助?哪些是违规求助? 9559576
关于积分的说明 21750809
捐赠科研通 7757392
什么是DOI,文献DOI怎么找? 3429167
关于科研通互助平台的介绍 2553530
邀请新用户注册赠送积分活动 2473923